je.st
news
Tag: present
Kentucky court says students must be given Miranda warnings if police are present
2013-04-26 17:32:00| American School & University
State supreme court suppresses student's incriminating statement because he wasn't apprised of his rights. Safety at School read more
Tags: present
court
students
police
Regal Beloit Corporation to Present at the Wells Fargo 2013 Industrial and Construction ...
2013-04-26 06:00:00| Industrial Newsroom - All News for Today
(Beloit, WI): Regal Beloit Corporation (NYSE:RBC) will be presenting at the Wells Fargo 2013 Industrial and Construction Conference on May 8, 2013 at 4:30 pm EDT.<br /> <br /> The presentation will be webcast and can be accessed at: <a href="http://cc.talkpoint.com/well001/050813a_hr/?entity=9_SDKIX64">http://cc.talkpoint.com/well001/050813a_hr/?entity=9_SDKIX64</a>.<br /> <br /> An archive of the audio webcast will be available for 90 days following the presentation at the link referenced ...
Tags: present
construction
industrial
corporation
AK Steel: Bleak Present, Promising Future
2013-04-25 13:56:08| Steel - Topix.net
AK Steel has recently released its quarterly results. The company reported a net loss of $9.9 mln or $0.07 per share.
Tags: present
future
steel
promising
Indium Corporation Product Manager to Present at IMAPS Workshop
2013-04-24 06:00:00| Industrial Newsroom - All News for Today
<a href="http://www.indium.com/">Indium Corporation</a>’s <a href="http://www.indium.com/biographies/andy-mackie/">Andy C. Mackie, PhD, MSc</a>, will share his expertise at the <a href="http://www.imaps.org/nano/index.htm">IMAPS Advanced Technology Workshop on Packaging the Next Generation of Nano Devices</a> April 30-May 1 in Albany, N.Y. <br /> <br /> Dr. Mackie’s presentation, Wafer Bumping Fluxes Enabling 2.5D and 3D Technology, examines the theoretical and experimental spin ...
Tags: product
present
manager
corporation
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress
2013-04-23 12:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. MK-5172 is an investigational, once-daily, oral HCV NS3/4A protease inhibitor that in preclinical evaluations has demonstrated a high barrier to resistance. Language: English Contact HTML: MerckMedia Contact:Caroline Lappetito, 267-305-7639orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
international
updated
Sites : [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] next »